Resona Asset Management Co. Ltd. Has $1.23 Million Stake in BioMarin Pharmaceutical Inc. $BMRN

Resona Asset Management Co. Ltd. decreased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 73.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 20,696 shares of the biotechnology company’s stock after selling 56,136 shares during the period. Resona Asset Management Co. Ltd.’s holdings in BioMarin Pharmaceutical were worth $1,230,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of BMRN. Viking Global Investors LP increased its holdings in shares of BioMarin Pharmaceutical by 13.8% in the second quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock valued at $675,505,000 after purchasing an additional 1,488,552 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of BioMarin Pharmaceutical by 6.3% in the third quarter. AQR Capital Management LLC now owns 5,932,109 shares of the biotechnology company’s stock valued at $321,283,000 after purchasing an additional 351,536 shares in the last quarter. Capital Research Global Investors increased its holdings in shares of BioMarin Pharmaceutical by 547.5% in the third quarter. Capital Research Global Investors now owns 2,537,596 shares of the biotechnology company’s stock valued at $137,436,000 after purchasing an additional 2,145,717 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of BioMarin Pharmaceutical by 42.7% in the third quarter. Dimensional Fund Advisors LP now owns 2,245,186 shares of the biotechnology company’s stock valued at $121,597,000 after purchasing an additional 671,566 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in shares of BioMarin Pharmaceutical by 0.4% in the third quarter. Northern Trust Corp now owns 1,662,268 shares of the biotechnology company’s stock valued at $90,028,000 after purchasing an additional 7,157 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, EVP Gregory R. Friberg sold 6,326 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $60.38, for a total value of $381,963.88. Following the transaction, the executive vice president directly owned 37,578 shares of the company’s stock, valued at approximately $2,268,959.64. This trade represents a 14.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Charles Greg Guyer sold 16,486 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $60.46, for a total transaction of $996,743.56. Following the completion of the transaction, the executive vice president directly owned 79,953 shares in the company, valued at approximately $4,833,958.38. The trade was a 17.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 26,093 shares of company stock worth $1,555,389. Insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on BMRN. Stifel Nicolaus set a $68.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, February 24th. Guggenheim lowered their price target on shares of BioMarin Pharmaceutical from $106.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Piper Sandler lowered their price target on shares of BioMarin Pharmaceutical from $122.00 to $84.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Barclays raised their price target on shares of BioMarin Pharmaceutical from $80.00 to $105.00 and gave the company an “overweight” rating in a report on Tuesday, March 3rd. Finally, Oppenheimer lowered their price target on shares of BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating for the company in a report on Tuesday, February 24th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $88.67.

BioMarin Pharmaceutical Price Performance

Shares of BMRN stock opened at $54.09 on Friday. BioMarin Pharmaceutical Inc. has a 52-week low of $49.26 and a 52-week high of $66.28. The stock has a market cap of $10.45 billion, a PE ratio of 39.48, a PEG ratio of 0.41 and a beta of 0.23. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.20 and a current ratio of 5.81. The firm’s 50 day moving average price is $54.56 and its two-hundred day moving average price is $56.24.

Key BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin said Voxzogo met its main goal in a late-stage hypochondroplasia study, supporting plans to file with the FDA in 2026 and boosting investor optimism about another potential growth driver. Article Title
• Positive Sentiment: Analyst commentary remained constructive overall, with Canaccord Genuity cutting its price target to $111 from $116 but reiterating a buy rating, implying substantial upside from current levels. Article Title
• Neutral Sentiment: Several press items from The Globe and Mail and TipRanks highlighted additional analyst coverage on BMRN, but they did not add a clear new operating catalyst beyond general sentiment and valuation commentary. Article Title
• Neutral Sentiment: BioMarin’s Phase 3 ENERGY 3 trial of BMN 401 met one co-primary endpoint but missed the other, making the readout mixed rather than clearly successful. Article Title
• Negative Sentiment: The mixed BMN 401 results triggered a notable selloff, with investors reacting to uncertainty around the drug’s commercial prospects and the likelihood of a clean regulatory path. Article Title

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.